Medical nanomaterial characterization analysis is the systematic evaluation of the physicochemical properties of nanoscale materials used in drug delivery systems, medical devices, implants, and in vitro diagnostics. Because properties such as particle size, surface charge, morphology, and chemical composition directly determine the safety, efficacy, and regulatory acceptability of nano-enabled medical products, comprehensive characterization is essential at every stage from research and development to batch release. This technical article reviews the types of medical nanomaterials tested, key analytical parameters, standard testing methods, relevant ISO and ASTM standards, and frequently asked questions.
Technical Overview
Medical nanomaterials are engineered materials with at least one external dimension in the nanoscale range (approximately 1–100 nm) that are intended for therapeutic, diagnostic, or device-related applications. At this scale, materials exhibit size-dependent behavior—such as enhanced reactivity, altered optical or magnetic properties, and increased surface-to-volume ratios—that cannot be predicted from their bulk counterparts. Consequently, regulators and standards bodies require robust physicochemical characterization data before nanomaterials can be incorporated into clinical products.
Characterization analysis for medical nanomaterials typically follows a multi-attribute approach described in ISO/TR 13014, which guides the physicochemical characterization of engineered nanomaterials for toxicological assessment, and ISO 10993-22, which addresses biological evaluation of medical devices containing nanomaterials. Key attributes include particle size and size distribution, morphology, agglomeration state, surface charge, surface chemistry, composition and purity, crystal structure, and dissolution behavior. Reliable characterization supports formulation optimization, batch-to-batch consistency, stability studies, comparability exercises, and regulatory submissions reviewed by agencies such as the FDA and EMA.
Accredited third-party laboratories specializing in nanomaterial analysis combine complementary instrumental techniques, since no single method can fully describe a nanoparticle system. Orthogonal measurement—for example, pairing dynamic light scattering with electron microscopy—is widely recognized as best practice for reducing analytical bias and satisfying data quality expectations under ISO/IEC 17025-accredited testing frameworks.
Testing Samples
Inorganic and Metallic Nanoparticles
Gold nanoparticles used in lateral-flow assays and photothermal therapy, silver nanoparticles for antimicrobial coatings, superparamagnetic iron oxide nanoparticles (SPIONs) for MRI contrast and hyperthermia, and metal oxide particles such as titanium dioxide, zinc oxide, and nanohydroxyapatite for dental and orthopedic applications. Typical test articles include powders, colloidal dispersions, and functionalized conjugates.
Polymeric Nanocarriers
Nanoparticles and nanocapsules prepared from biodegradable polymers such as PLGA, PLA, and PCL, as well as polymeric micelles and dendrimers. These samples are commonly submitted for size distribution, drug loading, encapsulation efficiency, and in vitro release testing.
Lipid-Based Nanomaterials
Liposomes, solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and lipid nanoparticles (LNP) used for mRNA and siRNA delivery. Characterization focuses on hydrodynamic diameter, polydispersity index, zeta potential, lipid composition, and encapsulated payload integrity.
Carbon-Based and Silica Nanomaterials
Carbon nanotubes, graphene and graphene oxide nanosheets, fullerenes, and mesoporous silica nanoparticles used in biosensing, drug delivery, and tissue engineering scaffolds.
Quantum Dots and Exosomes
Semiconductor quantum dots (CdSe/ZnS, InP-based) for fluorescence imaging and diagnostics, and biological nanovesicles such as exosomes and extracellular vesicles intended for therapeutic and biomarker applications.
Nano-Engineered Medical Device Surfaces
Nanocoatings on implants, catheters, and wound dressings, including antimicrobial silver layers, nanostructured hydroxyapatite, and drug-eluting nanolayers, which require surface chemical and topographical analysis.
Testing Items
Core physicochemical parameters routinely evaluated for medical nanomaterials include:
- Particle size, size distribution (D10/D50/D90), and polydispersity index (PDI)
- Particle morphology, shape, and structure by microscopy
- Agglomeration and aggregation state in relevant media
- Zeta potential and colloidal stability
- Specific surface area, pore size distribution, and porosity
- Elemental composition, purity, and impurity profiling
- Crystal structure, phase identification, and crystallinity
- Surface chemistry, functional groups, coating density, and ligand conjugation
- Drug loading content and encapsulation efficiency
- In vitro drug release kinetics and dissolution or ion-leaching behavior
- Thermal properties, melting behavior, and thermal stability
- Optical properties such as plasmon resonance absorption
- Magnetic properties for iron oxide systems
- Endotoxin level, bioburden, and sterility-related attributes for clinical-grade materials
- Storage and accelerated stability monitoring of particle size, PDI, and payload
Testing Methods
Electron and Scanning Probe Microscopy
Transmission electron microscopy (TEM), high-resolution TEM, scanning electron microscopy (SEM), and atomic force microscopy (AFM) provide direct visualization of particle morphology, core diameter, and aggregation state. AFM size measurement of nano-objects follows ASTM E2859, while energy-dispersive X-ray spectroscopy (EDS/EDX) coupled with SEM or TEM maps elemental distribution.
Light Scattering and Particle Tracking
Dynamic light scattering (DLS) measures hydrodynamic diameter and PDI of colloidal suspensions in accordance with ISO 22412; electrophoretic light scattering determines zeta potential under ISO 13099; nanoparticle tracking analysis (NTA) provides particle-by-particle size distribution and concentration per ISO 19430; and laser diffraction covers broader size ranges in line with ISO 13320 and ASTM B822.
Surface and Pore Analysis
Brunauer–Emmett–Teller (BET) gas adsorption determines specific surface area according to ISO 9277, while pore size and volume of mesoporous materials are assessed per the ISO 15901 series. Contact angle measurement evaluates surface wettability of nanocoated device surfaces.
Spectroscopic and Structural Characterization
X-ray diffraction (XRD) identifies crystalline phases and estimates crystallite size via the Scherrer equation; Fourier-transform infrared spectroscopy (FTIR) and Raman spectroscopy confirm functional groups and ligand attachment; X-ray photoelectron spectroscopy (XPS) probes surface elemental composition and oxidation states in line with ISO 15472; UV-Vis spectroscopy characterizes plasmonic nanoparticles and quantifies conjugates.
Compositional and Thermal Analysis
Inductively coupled plasma mass spectrometry (ICP-MS) or ICP-OES quantifies elemental composition, metal content, and dissolution kinetics, supporting impurity assessment under ICH Q3D principles. Thermogravimetric analysis (TGA) measures residual solvents, coating content, and thermal stability, and differential scanning calorimetry (DSC) evaluates phase transitions and polymorphic form.
Performance and Biological Quality Testing
Size-exclusion chromatography (SEC) and HPLC determine drug loading, encapsulation efficiency, free versus bound payload, and in vitro release profiles. Endotoxin testing by the LAL method (USP <85> / EP 2.6.14) and microbial enumeration per ISO 11737-1 support clinical-grade quality expectations. Biological safety screening is planned in accordance with the ISO 10993 series and ISO 10993-22 for devices incorporating nanomaterials.
Applications
Medical nanomaterial characterization analysis serves stakeholders across the healthcare product lifecycle:
- Nanomedicine development: formulation screening, optimization, and comparability for liposomal drugs, polymeric nanoparticles, and mRNA lipid nanoparticles
- Regulatory submission support: physicochemical data packages for IND, NDA, BLA, and CE technical documentation
- Medical device qualification: evaluation of antimicrobial nanocoatings, nanostructured implant surfaces, and drug-eluting layers
- Quality control and batch release: routine verification of size, PDI, zeta potential, and content against predefined specifications
- Stability and shelf-life studies: real-time and accelerated condition monitoring under ICH guidance
- Nanosafety assessment: input data for toxicological evaluation per ISO/TR 13014 and ISO 10993-22, including dissolution and ion-release testing
- Academic and industrial research: mechanistic studies of targeted delivery, imaging agents, biosensors, and tissue engineering scaffolds
FAQ
Why is orthogonal characterization recommended for nanomaterials?
Each technique measures a different attribute—for example, DLS reports hydrodynamic diameter of particles in suspension, while TEM images the dried core diameter. Combining multiple methods compensates for individual method limitations and provides a defensible, comprehensive dataset for regulatory review.
How much sample is required for typical characterization?
Requirements vary by technique: DLS and zeta potential may need less than 1 mL of dilute dispersion, electron microscopy requires only microliters, while BET surface area may require tens to hundreds of milligrams of powder. Accredited third-party laboratories can advise on minimum quantities for each test item.
Which standards govern particle size measurement of nanomaterials?
ISO 22412 covers DLS, ISO 19430 covers particle tracking analysis, ISO 13099 covers zeta potential determination, ISO 13320 and ASTM B822 cover laser diffraction, and ASTM E2490 provides guidance on interpreting particle size distributions of nanomaterials.
Why is zeta potential important for medical nanomaterials?
Zeta potential reflects surface charge and is a practical indicator of colloidal stability. Particles with sufficiently high magnitude of zeta potential tend to resist aggregation, which affects shelf life, in vivo dispersion, injection performance, and biological interactions such as protein adsorption and cellular uptake.
Are characterization reports from accredited laboratories accepted by regulators?
Yes. Reports generated by ISO/IEC 17025-accredited third-party laboratories, executed with validated methods and traceable standards, are widely accepted by regulatory agencies and notified bodies in support of technical documentation and submissions.
Can characterization be performed on nanomaterials within a finished device?
Yes. Extractables, released particles, and surface-bound nanolayers can be evaluated using a combination of microscopy, surface analysis, and elemental techniques, following the risk-based approach described in ISO 10993-22 for devices containing nanomaterials.